Navigation Links
Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
Date:7/24/2012

effects of their current opioid. 

Relmada Therapeutics is led by an experienced management team.  CEO Sergio Traversa PharmD, MBA has over twenty-five years of experience in the healthcare sector in the United States and Europe, ranging from management positions in the major pharmaceutical industry at Eli Lilly where he participated in the launch of Prozac and the early development of Zyprexa®, Strattera® and Cymbalta®, and Johnson & Johnson where he held the position of Area Manager for Southern Europe of Therakos Inc., a cancer and immunology division of the company, to investing and strategic advisory roles at leading healthcare focused financial institutions such as Mehta and Isaly, Merlin BioMed and Rx Capital.

Najib Babul, PharmD, is the President and Chief Scientific Officer of Relmada with over twenty years of experience in analgesic drug development.  Dr. Babul was V.P., Global Clinical Drug Development and Therapeutic Leader, Analgesia & Rheumatology at Scirex Corporation (now Premier Research), and Director, Clinical Research at Purdue Pharma.  He has designed studies and is an author on publications on MS Contin®, OxyContin®, Avinza®, Ultram® ER, Opana® ER, Codeine Contin®, sustained release hydromorphone and Dyloject®.  He is also Chair of the American Pain Society's Clinical Trials Special Interest Group and sits on the editorial board of the Journal of Opioid Management.

Danny Kao, PhD, JD, is Consulting Senior Vice President, Pharmaceutical Development of Relmada and has extensive formulation development experience.  He has developed a number of marketed extended release opioid dosage forms, including NDAs (New Drug Applications) and first to file ANDAs (Abbreviated New Drug Applications) and he has more than 20 issued or pending pa
'/>"/>

SOURCE Relmada Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... in measuring vibrational motion of a single molecule with ... of a single molecule differs from the behaviour of ... at the University of California, Irvine, where post-doctoral researcher ... a visiting fellow under professor Vartkess A. Apkarian, whose ... lead by Professor Eric O. Potma. The results of ...
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
(Date:8/20/2014)... BOSTON , Aug. 20, 2014  PAREXEL International ... it will be presenting at the Baird Healthcare Conference ... President and Chief Financial Officer, will be making a ... p.m. EDT on Wednesday, Sept. 3, 2014. ... through the "Investors" section of PAREXEL,s website at ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2
... Schering-Plough Corporation (NYSE: SGP ) will ... David Nicholson, Ph.D., senior vice president, Global Project Management ... Capital Global Healthcare Conference in Miami on Tuesday, March ... expected to talk about the company,s R&D pipeline and ...
... March 10 -- 29th Annual Cowen and Company Healthcare ... Gen-Probe Incorporated (Nasdaq: GPRO ) announced today ... Global Healthcare Conference in Miami on March 10, 2009 ... 29th Annual Cowen and Company Healthcare Conference in Boston ...
... also slated for presentation at American Academy of Dermatology ... March 5 Senetek PLC (OTC Bulletin Board: SNKTY), ... technologies that target the science of healthy aging, announced ... American Academy of Dermatology,s 67th Annual Meeting in San ...
Cached Biology Technology:Gen-Probe to Webcast Two Upcoming Investor Presentations 2Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 2Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 3
(Date:8/21/2014)... Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication ... today that its shares of common stock and the ... its proposed underwritten public offering of common stock and ... Capital Market, subject to closing of its proposed underwritten ... will trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- LiveScan ... has agreed to a partnership with Gabriel Health ... fastest growing Certified Nursing Assistant preparatory ... Institute  an exclusive member of Binary,s LiveScan service ... Biometrics will improve its service capabilities by ...
(Date:8/21/2014)... AWI geologist Juliane Mller the Fram Strait is a key ... of this passage between Greenland and Svalbard warm Atlantic water ... the west side cold Arctic water masses and sea ice ... Atlantic. A considerable portion of the Atlantic water cools here ... layers. The circulation of the water caused in this manner ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
... (Philadelphia, PA) The stop and start of blood flow ... severe damage to heart cells, reducing their capacity to function ... by researchers at Temple University School of Medicine suggests that ... using a drug. In experiments in mice that recapitulated a ...
... Researchers have linked a species of intestinal bacteria known as ... the first demonstration in humans that the chronic inflammatory joint ... The new findings by laboratory scientists and clinical researchers in ... evidence that the trillions of microbes in our body play ...
... help inform research to stem the spread of malaria. ... researchers fresh insights into the behaviour of these tiny life ... pave the way for improved prevention and control of this ... world,s population. Malaria parasites mate in the gut ...
Cached Biology News:Breakthrough by Temple researchers could lead to new treatment for heart attack 2Breakthrough by Temple researchers could lead to new treatment for heart attack 3Study links intestinal bacteria to rheumatoid arthritis 2Study links intestinal bacteria to rheumatoid arthritis 3Study links intestinal bacteria to rheumatoid arthritis 4
UBC13 Antibody...
Request Info...
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Biology Products: